Across EULAR 2026 abstracts this year and presented in a session called “this is a woman’s world”, strong signals are emerging that the menopausal transition is associated with changes in disease phenotype, disease activity, and treatment response in both RA and PsA.
All News
Article
Article
The last day in London was exciting as both the Late-Breaking abstracts and new EULAR guidelines were presented.
Article
Day 3 was an interesting mix of posters, oral presentations, and review sessions on many practical subjects like osteoarthritis, large vessel vasculitis, systemic sclerosis, and pregnancy. Here are a few of my recommended abstracts from Friday at EULAR 2026.
Article
At EULAR 2026, Dr Nikolaos Kougkas presented data from a unique real-world cohort built within joint dermatology–rheumatology university centers, following 394 patients with psoriasis on bDMARDs for up to 17 years. We sat down with Dr Kougkas to unpack the methodology, challenge the results, and draw out the clinical implications for everyday practice.
The pain that inflammation does not explain in SpA and PsA
At EULAR 2026, the NEUPIA study (OP0317), a prospective observational investigation conducted at KU Leuven and University Hospitals Leuven, provides the most detailed longitudinal characterisation to date of these https://t.co/OYMf4KKBc1
Risk of Parkinsons? RA patients have 28% lower Parkinson's risk vs general population (HR 0.72); axSpA had HIGHER risk (HR 1.29). Non-TNF biologics in RA reduced PD risk further (HR 0.74). No effect seen in PsA/axSpA. #EULAR2026 Abstr #POS1116 https://t.co/1vZoZGEu5Z
Do probiotics improve disease activity in PsA?
POS0290: no
MEDISPA RCT n=66
Multispecies probiotics not superior to placebo at week 12
#EULAR2026 @RheumNow https://t.co/1byJ1nB4GF
Antoni Chan MD (Prof)
Tweet
LB0001: Bimekizumab SUPERIOR to risankizumab on ACR50 in active #PsA 49.1% vs 38.4% (p=0.0078). First ever H2H biologic superiority on joints in PsA. #Bimekizumab @RheumNow #EULAR2026 https://t.co/6waepYs9RK
#EULAR2026 LB0001 BOLD results in #PsA. First H2H RCT showing superiority of Bimekizumab (IL17A- & F-i) vs Risankizumab (IL-23-i) in primary endpoint, ACR50 49% vs 38% at WK16. The difference was seen from WK4 & sustained to WK24. May help inform choice of Tx @RheumNow #EULARBest https://t.co/s4zbFiepuP
Antoni Chan MD (Prof)
Tweet
ACR50 at Week 4 was 19.9% (BKZ) vs 7.2% (RZB) nominal p<0.0001. Faster onset, higher sustained joint response. DAPSA LDA/remission 65% vs 55%. Dual IL-17A/F blockade outperforms IL-23 inhibition for joints in #PsA. Abstr LB0001 @RheumNow #EULAR2026 https://t.co/s4z8r1rKte
First head-to-head trial to show #PsA joint outcome superiority
BE BOLD: Bimekizumab (BKZ; IL-17A/F dual blockade) beat Risankizumab (RZB: IL-23i) on ACR50 at wk 16 (49.1% vs 38.4%, p=0.0078). BKZ also faster: ACR50 at wk 4 already 19.9% vs 7.2%.
@RheumNow #EULAR2026 LB0001 https://t.co/YMQCpom5xD
Do GLP-1 agonists achieve meaningful weight loss in patients with RMDs?
RISE registry
Retrospective
N=60,206
Tirzepatide: lost 8%
Semaglutide: list 6%
At 12 months
PsA had the highest usage
OP0112 #EULAR2026 @RheumNow https://t.co/P3CTgiwqCr
One of the highlights of #EULAR2026 for me:
♀️The "This Is a Woman's World" session
I recapped 8 must-know abstracts (including our work from ARCH_ArLAR) in a new @RheumNow video🎬
https://t.co/3jwJIegGg4 via @YouTube
@ArLARheumatolog https://t.co/Azvkl2sjdu
Beyond the Scale: Do GLP-1RAs Offer More Than Weight Loss in PsA?
Over 70% of patients with psoriatic arthritis (PsA) struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response.
https://t.co/pAIXkdazci https://t.co/vQTn3BWv2r
What does remission really mean to patients with #PsA? The RemiPPsA international qualitative study asked 123 patients across 11 countries. Pain-free + ability to resume daily life topped the list, not just composite scores. #EULAR2026 @RheumNow, POS0294 https://t.co/mEGpkewuTX
Aurelie Najm
Tweet
No big surprise here, deucravacitinib does as well without MTX
Pooled analysis of 52wk data of POETYK PSA
Same ACR20/50/70 and MDA response profiles also similar safety profiles
#POS0288 #EULAR2026 @RheumNow https://t.co/XqLfZstRuS
Oral TYK2i deucravacitinib works for #PsA with OR without methotrexate. Pooled POETYK data (n=648): ACR20/50/MDA, enthesitis, dactylitis, skin responses, and PROs all comparable regardless of MTX use at wk 52. Good news for pts who can't tolerate MTX. @RheumNow #EULAR2026 POS0288
Aurelie Najm
Tweet
What does remission look like for people living with PsA?
Much more than the absence of swollen joints
Absence of pain
Skin management
Ability to resume daily activities
Sustained over time
A definition not always reflected in our disease activity scores
#POS0294 #EULAR2026 https://t.co/VCnMGAOVYm
sheila
Tweet
In this posthoc analysis of pooled data from BE MOBILE 1&2, BKZ showed ⬆️clinical imprvements vs. PBO at 1 yr regardless of age, BMI, HLAB27 status & CRP.
At wk 52, ASAS40/ASDAS <2.1 was higher in pts w/BKZ who were ≤35y, BMI ≥25–<30 or HLA-B27+
POS0949 @RheumNow #EULAR2026 https://t.co/9sfil6y5Qr
